The relationships between IFNL4 genotype, intrahepatic interferon-stimulated gene expression and interferon treatment response differs in HCV-1 compared with HCV-3

Jacinta A Holmes, Mario Congiu, Sara Bonanzinga, Manjeet K Sandhu, Y H Kia, Sally J Bell, Tin Nguyen, David M Iser, Kumar Visvanathan, William Sievert, David Scott Bowden, Paul V Desmond, Alexander James V Thompson

Research output: Contribution to journalArticleResearchpeer-review

10 Citations (Scopus)

Abstract

BACKGROUND: The biological mechanism underlying the association between IFNL4/IFNL3 polymorphism and peginterferon/ribavirin (PR) response in HCV-1 is thought to involve differential intrahepatic interferon-stimulated gene expression. HCV-3 is more sensitive to PR, but there are no studies of the association between IFNL4 polymorphism, PR treatment response and liver interferon-stimulated gene expression in HCV-3. AIM: We evaluated the association between IFNL4/IFNL3 genotypes, PR treatment outcomes and intrahepatic interferon-stimulated gene expression, according to HCV genotype. METHODS: HCV-1 and HCV-3 patients who received PR therapy were identified. IFNL3 (rs12979860) and IFNL4 genotype (rs368234815) were determined. A second cohort with stored liver specimens was identified. Expression of ISGs was measured by rt-PCR. RESULTS: Two hundred and fifty-nine patients were identified: 55 HCV-1, 45 HCV-3. IFNL4 genotype frequency was TT/TT 44 , TT/DeltaG 42 andDeltaG/DeltaG 14 . Linkage disequilibrium with IFNL3 genotype was high (r(2) = 0.98). The association between IFNL4 genotype and PR response was attenuated in HCV-3 vs. HCV-1 (HCV-3: SVR 89 vs. 76 vs. 72 for TT/TT vs. TT/DeltaG vs. DeltaG/DeltaG, P = 0.09; HCV-1: SVR: 82 vs. 29 vs. 24 , P <0.001). Intrahepatic ISG expression was evaluated in 92 patients; 61 HCV-1. The association between IFNL4 genotype and liver ISG expression was significantly different for HCV-3 vs. HCV-1 (P-value for interaction = 0.046), with levels of interferon-stimulated gene expression being highest in HCV-1 patients who carried a poor-response IFNL4 genotype. CONCLUSIONS: The relationship between IFNL4 genotype and PR treatment response as well as intrahepatic interferon-stimulated gene expression differs between HCV-1 and HCV-3. These data suggest fundamental differences in host-virus interactions according to HCV genotype.
Original languageEnglish
Pages (from-to)296 - 306
Number of pages11
JournalAlimentary Pharmacology & Therapeutics
Volume42
Issue number3
DOIs
Publication statusPublished - 2015

Cite this